CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S ...

Moderna Inc. (NYSE: MRNA) has revised its sales projections for 2025, lowering expectations due to sluggish demand for its ...

A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation. Moderna is a leader in the creation of the field of mRNA medicine. Through the ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...